Endothelin receptor antagonists in a beagle model of pulmonary hypertension: Contribution to possible potential therapy?  by Okada, Morihito et al.
JACC Vol. 25, No. 5 1213 
April 1995:1213-7 
Endothelin Receptor Antagonists in a Beagle Model of Pulmonary 
Hypertension: Contribution to Possible Potential Therapy? 
MORIH ITO OKADA, MD, CHOJ IRO YAMASHITA,  MD, MASAYOSHI OKADA, MD, 
KENJI OKADA, MD 
Kobe, Japan 
Objectives. This study investigated the pharmacologic effect of 
endothelin receptor antagonists on cardiopulmonary hemody- 
namic variables in a beagle model of pulmonary hypertension. 
Background. We recently developed a beagle model of pulmo- 
nary hypertension that allows accurate determination of cardio- 
pulmonary hemodynamic variables and is associated with ele- 
vated plasma endothelin-1 concentrations imilar to those in 
pulmonary hypertension in humans. 
Methods. Twelve beagles (pulmonary hypertension, n = 6; 
control group, n = 6) were studied during baseline conditions and 
during right atrial infusion of FR139317 (an ETA receptor 
antagonist), RES-701-1 (an ETB receptor antagonist), nitroglyc- 
erin and prostaglandin E1. Pulmonary hypertension was induced 
in experimental beagles 8 weeks after injection with 3 mg/kg body 
weight of dehydromonocrotaline. 
Results. FR139317 lowered pulmonary artery and systemic 
arterial pressures in both pulmonary hypertensive and control 
beagles, with a significantly greater effect on pulmonary artery 
pressure in pulmonary hypertensive dogs. RES-701-1 tended to 
increase pulmonary artery pressure only in pulmonary hyperten- 
sive beagles. Nitroglycerin depressed pulmonary artery and sys- 
temic arterial tone equally well in control and pulmonary hyper- 
tensive animals. Prostaglandin E1 produced a greater decrease in 
systemic arterial pressure in pulmonary hypertensive than in 
normal beagles despite having the same effect on pulmonary 
artery pressure in both. 
Conclusions. ETA receptor antagonists decrease pulmonary 
artery pressure in a beagle model and may therefore be clinically 
useful for treatment of pulmonary hypertension. 
(JAm CoU Cardiol 1995;25:1213-7) 
Clinical use of vasodilator therapy for pulmonary hypertension 
has yielded inconsistent results (1,2), largely because of such 
adverse ffects as systemic hypotension, right ventricular isch- 
emia, arrhythmias, arterial oxygen desaturation a d exacerba- 
tion of pulmonary hypertension (3-5). The ideal vasodilator 
agent for pulmonary hypertension would specifically lower 
pulmonary artery pressure and minimize the risk of systemic 
complications. Clinical studies have shown considerable varia- 
tion in the response to vasodilator agents in small numbers of 
pulmonary hypertensive patients. This variability may reflect 
differences inpulmonary vascular pathophysiology as well as in 
the dose, timing and route of administration f therapeutic 
agents. Nonrandomized studies using vasodilator therapy 
(2,6-8) have been performed as a result of the concept hat 
pulmonary hypertension was caused by pulmonary vasocon- 
striction in response to an external stimulus (9,10). Unfortu- 
nately, such therapy has not been demonstrated to improve 
survival (8). Because thorough comparative studies in humans 
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are impossible, we developed an animal model of pulmonary 
hypertension in a relatively large animal to evaluate cardiopul- 
monary hemodynamic variables accurately. Pulmonary hyper- 
tension can be induced in beagles by injection of 3 mg/kg body 
weight of dehydromonocrotaline (11). 
Recent studies have examined the role of abnormal pulmo- 
nary endothelial cell function in pulmonary hypertension 
(12,13) and established that elevated plasma concentrations of 
endothelin-1 are associated with pulmonary hypertension (14- 
17). The finding that our model showed elevated plasma 
endothelin-1 concentrations similar to clinical pulmonary hy- 
pertension prompted us to consider whether endothelin recep- 
tor antagonists might be etficacious for the treatment of 
pulmonary hypertension. This study was therefore designed to 
investigate he hemodynamic response of the cardiopulmonary 
circulation to the endothelin ETA receptor antagonist FR139317 
and the ETB receptor antagonist RES-701-1 in dehydromono- 
crotaline-induced pulmonary hypertensive beagles. Physiologic 
effects were compared with those of the vasoactive agents nitro- 
glycerin and prostaglandin E 1. 
Methods  
Study protocol. Twelve purebred beagles (mean age 3 
months, mean [_+SD] weight 5.7 _+ 1.3 kg) were studied. 
Before initiation of an experiment, each beagle was anesthe- 
tized with sodium pentobarbital (25 mg/kg intravenously) and 
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permitted to breathe spontaneously. At a venous infusion port, 
a 5F flow-directed pulmonary artery thermodilution catheter 
(Baxter Healthcare Corporation) was introduced, and cardiac 
output was determined by taking the mean of at least three 
measurements recorded by a cardiac output computer. An- 
other catheter was placed in the femoral artery for monitoring 
systemic arterial pressure. Arterial and intracardiac pressures 
were measured by a polygraph (363, NEC San-ei Instruments 
Ltd.) and recorded (8M14, NEC San-ei Instruments Ltd.). We 
injected 3 mg/kg of dehydromonocrotaline, which was pre- 
pared from monocrotaline (18), into the right atrium of the 
beagles and investigated cardiopulmonary hemodynamic vari- 
ables at 8 weeks after injection. A blood sample was collected 
from the pulmonary artery for determining the plasma 
endothelin-1 concentration. Each blood sample was placed in 
a chilled tube containing ethylenediaminetetraacetic acid 
(EDTA) and aprotinin, and after centrifugation, the plasma 
was stored at -30°C until used. After endothelin-I had been 
extracted through Cls (Waters Associates), the concentration 
was measured by radioimmunoassay with the use of an anti- 
endothelin-1 antibody (Peninsula Lab. Inc.) and iodine-125- 
labeled endothelin-I (Amersham Japan Co.). 
FR139317 (Fujisawa Pharmaceutical Co., Ltd.) and RES- 
701-1 (Kyowa Hakko Kogyo Co., Ltd.) were infused at doses of 
40 or 200 and 20 or 100 t~g/kg per rain, respectively. We 
determined the infusion dose of nitroglycerin and prosta- 
glandin E1 that reduced pulmonary arterial pressures by -20% 
in our pulmonary hypertension model. The appropriate doses 
were found to be 10 and 0.4 t~g/kg per rain for nitroglycerin 
and prostaglandin El, respectively. FR139317 was dissolved in 
1 N sodium hydroxide, and RES-701-1 was dissolved in di- 
methylsulfoxide. Nitroglycerin and prostaglandin E I were dis- 
solved in sterile water. All solutions were prepared on the day 
of the study and kept on ice until administered. All drugs were 
delivered through the pulmonary artery by an infusion pump. 
Under sterile conditions, baseline values were obtained with 
infusion of vehicle for 30 rain, followed by infusion of the drug, 
each given for 30 min. 
Hemodynamic variables. Hemodynamic variables were 
measured uring the last 5 rain of each infusion. There was a 
pause of 24 h between infusion of different drugs. Therefore, 
we believed that there were no interactions between the 
treatments with different drugs administered to the same 
beagles. The experiments were performed inthe same order of 
drug administration in every beagle at baseline and at 8 weeks 
after dehydromonocrotaline. Systemic vascular esistance was 
calculated by subtracting mean right atrial pressure (ram Hg) 
from mean systemic arterial pressure (ram Hg) and dividing by 
cardiac output (liters/min). Pulmonary vascular esistance was 
calculated by subtracting mean wedge pressure (ram Hg) from 
mean pulmonary artery pressure (ram Hg) and dividing by 
cardiac output. Both values were expressed as dynes.s.cm s by 
multiplying the values obtained by a factor of 80. The percent 
change in the variables was calculated as follows: (Postinjec- 
tion value - Preinjection value)/Preinjection value. All beagles 
were kept in clean cages, with regular food and sterile water as 
desired, and received humane care in compliance with the 
"Principles of Laboratory Animal Care" formulated by the 
Institute of Laboratory Animal Resources and the "Guide for 
the Care and Use of Laboratory Animals" published by the 
National Institutes of Health. 
Statistical analysis, All data are given as the mean value _+ 
SD. Data and variables were compared using one-way 
repeated-measures analysis of variance to determine the effect 
of debydromonocrotaline a d to compare the efficacies of 
different drugs. When the one-way repeated-measures analysis 
of variance was significant, he differences were tested by the 
Sheff~ F test; p < 0.05 was considered significant. 
Results 
Development of pulmonary hypertension i  dehydromono- 
crotaline-treated beagles. A single injection of dehydromono- 
crotaline produced a significant elevation in pulmonary artery 
pressure compared with the preinjection value. During the 8 
weeks after injection, systolic pulmonary artery pressure, mean 
pulmonary artery pressure and pulmonary vascular esistance 
increased significantly from 21.1 + 2.4 to 55.9 z 8.3 mm Hg, 
from 11.8 _+ 1.8 to 33.2 + 5.9 mm Hg and from 196 +_ 33 to 
1,237 _+ 441 dyne.s.cm -5, respectively. Cardiac output de- 
creased significantly from 2.0 _+ 0.2 to 1.7 + 0.3 liters/rain. 
Heart rate, systemic arterial pressure, right atrial pressure, 
pulmonary capillary wedge pressure and systemic vascular 
resistance remained relatively stable and revealed no signifi- 
cant differences. Plasma endothelin-1 levels increased signifi- 
cantly from 1.25 + 0.23 to 3.12 + 1.06 pg/ml. 
Hemodynamie ffects of drug infusion in normal beagles. 
The physiologic responses to the four drugs in the six normal 
beagles are shown in Table 1. FR139317 at doses of 40 or 
200 ~g/kg per rain or RES-701-1 at 20 or 100/~g/kg per rain 
caused no significant changes. Nitroglycerin at 10 t~g/kg per rain 
significantly decreased mean systemic arterial pressure (from 
115 _+ 6 to 94 _+ 6 mm Hg), pulmonary artery pressure (from 
11.8 _+ 1.8 to 9.7 _+ 2.0 mm Hg), systemic vascular esistance 
(from 4,511 +_ 458 to 3,618 + 383 dynes.s.cm -5) and pulmonary 
vascular resistance (from 196 _+ 33 to 141 + 32 dynes.s.cm s). 
Prostaglandin E 1 at 0.4 ~g/kg per rain significantly decreased 
mean pulmonary artery pressure (from 11.8 + 1.8 to 9.8 + 
0.8 ram Fig) and pulmonary vascular resistance (from 196 _+ 33 to 
135 _+ 40 dynes.s.cm -5)but did not produce significant effects in 
the systemic circulation. Heart rate and cardiac output were not 
altered by any of the drugs tested. 
Hemodynamic effects of drug infusion in pulmonary hyper- 
tensive beagles. The physiologic responses to the four drugs in 
the six beagles with pulmonary hypertension are shown in 
Table 2. FR139317 at 200 /~g/kg per min significantly de- 
creased mean pulmonary artery pressure (from 33.2 + 5.9 to 
26.8 _+ 3.7 mm Hg) and pulmonary vascular esistance (from 
1,237 +_ 441 to 867 + 164 dynes.s.cm 5). FR139317 also 
decreased mean systemic arterial pressure and systemic vascu- 
lar resistance (p = NS). RES-701-1 at 100 /zg/kg per min 
increased mean pulmonary artery pressure (from 33.2 +_ 5.9 to 
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Table 1. Hemodynamic Values for Normal Beagles at Baseline and During Drug Infusion 
FR139317 RES-701-1 
Nitroglycerin Prostaglandin E l
Baseline 40 p.g/kg per min 2(10/*gAg per min 20 p.g/kg per rain 100/,g/kg per rain (10 gg/kg per min) (0.4/zg/kg per min) 
HR (beats/rain) 124 + 13 lPZ~ = 14 /25 _+ 16 123 ,+ 13 123 = 12 127 ± 16 130 -+ 14 
MSAP (nun Hg) 115 + 6 115 _- 8 109 = 9 116 ± 9 116 ± i0 94 ± 6* ll0 ± I1 
MPAP (mm Hg) 11.8 = 1.8 ll.7 = 2.1 11.3 _+ 2.5 12.0 ,+ 1.9 11.7 = 2.3 9.7 ± 2.0* 9.8 _+ 0.8* 
CO (fiter~min) 2.0 ___ 0.2 1.9 + 0.2 1.9 _± 0.3 1.9 _+ 11.2 1.9 _+ 0.2 1.9 = 0.2 2.1 _+ 0.2 
SVR (dynes's.cm s) 4,511 _+ 458 4,595 _+ 651 4,426 _+ 66.3 4.651 + 568 4,60l = 563 3,618 _+ 383* 4,084 ± 586 
PVR (dynes.s.cm 5) 196±33 211,+82 195±52 198+69 211=76 141=32" 135=40' 
*p < 0.05, baseline versus drug infusions. Data presented are mean value _+ SD. CO - cardiac output; HR = heart rate; MPAP : mean pulmonary artery pressure; 
MSAP = mean systemic arterial pressure; PVR (SVR) - pulmonary (systemic) vascular esistance. 
36.2 _+ 6.4 mm Hg) but did not affect pulmonary vascular 
resistance, mean systemic arterial pressure or systemic vascular 
resistance. Nitroglycerin at 10 pg/kg per rain significantly 
decreased mean systemic arterial pressure (from 106 _+ 5 to 
87 _+ 6 mm Hg), pulmonary artery pressure (from 33.2 + 5.9 to 
27.0 _+ 5.1 mm Hg), systemic vascular resistance (from 4,685 _+ 
439 to 3,767 _+ 229 dynes.s.cm -s) and pulmonary vascular 
resistance (from 1,237 _+ 441 to 856 + 207 dynes.s.cm-5). 
Prostaglandin E t at 0.4 tzg/kg per rain significantly decreased 
mean systemic arterial pressure (from 106 _+ 5 to 93 + 
7 mm Hg), pulmonary artery pressure (from 33.2 _+ 5.9 to 
27.8 _+ 4.1 mm Hg), systemic vascular resistance (from 4,685 _+ 
439 to 3,718 + 120 dynes.s.cm -s) and pulmonary vascular 
resistance (from 1,237 _+ 441 to 870 + 243 dynes.s.cm 5). Both 
nitroglycerin at 10 /,g/kg per rain and prostaglandin Et at 
0.4/,g/kg per rain increased heart rate but did not produce 
significant differences. 
Vasodepressor effects of drug infusion on systemic arterial 
and pulmonary artery pressures. The decreases in mean 
systemic arterial and pulmonary artery pressures are summa- 
rized in Figure 1. FR139317 at 200/xg/kg per rain produced 
selectively reduced pulmonary artery pressure in pulmonary 
hypertensive beagles, with little effect on systemic arterial 
pressure in pulmonary hypertensive ornormal beagles (pulmo- 
nary artery and systemic arterial pressures, 14.6% and 5.2%, 
respectively, in pulmonary hypertensive beagles and 4.2% and 
4.8%, respectively in normal beagles). Nitroglycerin at 
10/xg/kg per rain produced a decrease in systemic arterial and 
pulmonary artery pressures. However, there were no signifi- 
cant differences in response between ormal and pulmonary 
hypertensive beagles (systemic arterial and pulmonary artery 
pressures 17.8% and 18.3%, respectively, in normal beagles 
and 18.2% and 18.6%, respectively, in pulmonary hypertensive 
beagles). Prostaglandin E 1 at 0.4 /xg/kg per rain caused a 
similar decrease in pulmonary artery pressure in normal and 
pulmonary hypertensive beagles but produced a greater de- 
crease in systemic arterial pressure in pulmonary hypertensive 
than in normal beagles (pulmonary artery pressure 15.5% and 
16.1%, respectively, in normal and pulmonary hypertensive 
beagles; systemic arterial pressure 11.0% and 4.1%, respec- 
tively, in normal and pulmonary hypertensive b agles). 
Discuss ion  
Reports that patients with either primary or secondary 
pulmonary hypertension had increased plasma endothelin-1 
concentrations (14-17) and injured vascular endothelial cells 
in the pulmonary circulation (19) inspired the series of exper- 
iments described in the present study. A single subcutaneous 
injection of monocrotaline causes pulmonary hypertension i
rats (20-24) and a progressive increase in plasma endothelin-1 
concentration (25). To examine the pharmacologic effects on 
the pulmonary vasculature, we sought a larger animal model of 
pulmonary hypertension i which cardiopulmonary hemody- 
namic variables could be accurately measured. We therefore 
established a beagle model of pulmonary hypertension i duced 
by right atrial injection of 3 mg/kg of dehydromonocrotaline. 
This experimental model has promising similarities to pulmonary 
hypertension i humans, which also develops long after induction 
by a variety of factors. Indeed, our pulmonary hypertension 
model showed an elevation in plasma endothelin-1 concentration 
similar to that in clinical pulmonary hypertension. This observa- 
Table 2. Hemcx]ynamic Values for Pulmonary Hypertensive Beagles at Baseline and During Drug Infusion 
FR139317 RES-701-1 
Baseline 40 gg/lg per min 200 ~g/kg per rain 20 gg/kg per rain 100/zg/kg per min 
Nitroglycerin 
(10 tzg/kg per rain) 
Prostaglandin Et
(0.4 ,agAg per min) 
HR (beats/min) 135 ± 13 135 + 10 136 ± 9 134 = 9 133 = 12 146 + 18 146 _+ 10 
MSAP (ram Hg) 106 : 5 105 _+ 6 101 + 7 105 + 5 109 z 6 87 _+ 6* 93 + 7* 
MPAP (nun Hg) 33.2 + 5.9 31.5 ___ 7.9 26.8 = 3.7* 34.5 __+ 6.0 36.2 + 6.4 27.0 ~ 5.1" 27.8 _+ 4.1' 
CO (liters/rain) 1.7 = 0.3 1.7 = 0.3 1.6 + 0.3 1.7 s (1.4 1.7 = 0.3 1.6 _+ 0.3 1.8 + 0,2 
SVR (dynes.s.cm s) 4,685 _+ 439 4,597 = 535 4,581 = 608 4,62l ± 693 4,77l ± 597 3,767 = 229* 3,718 _+ 120' 
PVR (dynes-s-era s) 1,237 ,+ 441 1,124 _+ 349 867 _+ 164' 1,272 +_ 351 1,319 ± 299 856 _+ 207* 870 _+ 243* 
*p < 0.05, baseline versus drug infusions. Data presented are mean value = SD. Abbreviations as in Table 1. 
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Tit 
Pit 
[ ]  Systemic arterial pressure 
[ ]  Pulmonary arterial pressure 
Normal PH Normal Normal PH 
FR139317 Nitroglycerin Prostaglandin El 
(200p g/kg/min) (10/~ g/kg/min) (0.4/z g/kg/min) 
Figure 1. Bar graph showing percent decrease in gradient (ram Hg) 
from baseline in normal and pulmonary hypertensive (PH) beagles. 
Differences among FR139317, nitroglycerin a d prostaglandin E1 are 
indicated. Data shown are mean value + SD. *p < 0.05 versus baseline 
value. 
tion formed the basis of our hypothesis that endothelin receptor 
antagonists might be effective in pulmonary hypertension. Be- 
cause drug therapy resulted in a decrease in both pulmonary 
artery pressure and pulmonary vascular esistance, some degree 
of reversible pulmonary vasoconstriction was present. This finding 
supported the validity of our model for comparison of the 
pulmonary vasodilator effect of the drugs under study. 
We considered the ideal pulmonary vasodilator response to 
be a decrease in both pulmonary artery pressure and pulmo- 
nary vascular esistance that exceeded the decrease in systemic 
arterial pressure and systemic vascular esistance. The effects 
of nitroglycerin have generally been attributed to decreased 
systemic venous tone, with a subsequent shift of blood from the 
heart and lungs to the systemic veins (26,27). In the present 
study, nitroglycerin was an effective vasodilator, but it lacked 
pulmonary vascular selectivity. Therefore, nitroglycerin had 
the least favorable hemodynamic profile. 
Prostaglandin E1 has generated interest because prosta- 
glandins may contribute to the physiologic regulation of pul- 
monary blood flow and because a deficiency of endogenous 
prostaglandins has been associated with primary pulmonary 
hypertension (28,29). Prostaglandin E1 is presently one of the 
most readily available prostaglandins for clinical use. Our data 
indicated that prostaglandin Et produced agreater decrease in
systemic arterial pressure in pulmonary hypertensive than 
normal beagles despite a similar decrease in pulmonary artery 
pressure in both groups. Progression of pulmonary hyperten- 
sion appears to prevent its selectivity as a pulmonary vasodi- 
lator. It has been proposed that the normally rapid pulmonary 
clearance of prostaglandin E l by 15-hydroxyprostaglandin e-
hydrogenase in the lungs (30,31) does not occur in pulmonary 
hypertension and that the active drug concentration i the 
systemic irculation therefore becomes elevated. 
Endothelin, which may be isolated from the supernatant of
cultured porcine endothelial cells, has potent vasoactivity (32) 
and may play an important role in the regulation of pulmonary 
vascular tone (33). At least two endothelin receptor subtypes, 
termed ETA and ETB, have been described (34,35). ETA 
receptors are located primarily on smooth muscle cells and 
mediate vasoconstriction, whereas activation of ETB receptors 
on endothelial or smooth muscle cells can cause vasodilation 
or vasoconstriction (36,37). Both ETA and ETB receptors 
coexist in the pulmonary circulation (38). The distribution of 
receptor subtypes, which varies with the vascular bed, may 
therefore explain differences in regional hemodynamic re- 
sponses to endothelin. 
There is some evidence that endothelin-1 has a potential 
role in pulmonary hypertension and is associated with altered 
vasoreactivity (39,40). Elevated plasma endothelin-1 concen- 
trations precede the development of pulmonary hypertension, 
suggesting that endothelin-1 may be involved in the pathogen- 
esis of pulmonary hypertension i monocrotaline-treated rats 
(25). Endothelin-1 activates ETA receptors, thereby causing 
vasoconstriction by intracellular signal transduction (41). If 
endothelin contributes to the progression of pulmonary hyper- 
tension, and endothelin receptors mediate vasoconstriction, 
then endothelin receptor antagonists might be clinically useful 
in the management of pulmonary hypertension. Although 
Miyauchi et al. (25) reported that infusion of BQ-123, a 
selective ETA receptor antagonist, concurrently with an 
injection of monocrotaline, inhibited the progression of 
monocrotaline-induced pulmonary hypertension i rats, they 
studied the effect of BQ-123 before the establishment of 
pulmonary hypertension. We found that reduction in pulmo- 
nary artery pressure by FR139317 was minor under basal 
conditions but that the vasodilator response was greatly en- 
hanced when vasoconstrictor tone was elevated. This observa- 
tion is consistent with excessive stimulation of ETA receptors 
in the pulmonary circulation by endogenous endothelin-1 in 
pulmonary hypertension and suggests a possible role of 
FR139317 for the blockade of endothelin-l-induced vasocon- 
striction. Our experiments showed that RES-701-1 increased 
pulmonary artery pressure only in pulmonary hypertensive 
beagles, although not significantly. This observation suggests 
that ETB receptors in our pulmonary hypertension model 
mediate pulmonary vasodilation but not vasoconstriction a d 
that pulmonary hypertension might be exacerbated by ETB 
receptor antagonists. 
Although the specific mechanism of action of endothelin 
receptor antagonists remains unclear, the present results have 
important therapeutic implications in the development of 
therapy for pulmonary hypertension. 
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